Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Novartis: Bimagrumab/BYM338 Bimagrumab is an antibody against activin type II receptor (ActRII) meaning that it acts as an ActRII antagonist (It prevents ActRII from functioning)
In searching Reddit communities dedicated to GLP-1 drugs, I found lots of normal people whose experience backed up that research: They had long tried to lose weight but could never quite meet their goals until they went on a GLP-1 drug
Pediatric Exclusivity: The Six-Month Bonus Round Pediatric exclusivity adds six months to any existing patents and regulatory exclusivity periods when a sponsor completes FDA-requested pediatric studies under the Best Pharmaceuticals for Children Act [3]
Whether those effects translate directly to women in the GLP-1-therapy-plus-weight-loss context requires additional research that hasn't been published yet
